A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.

Pfizer

Status and phase

Completed

Phase 3

Conditions

Hyperlipidemia

Hypercholesterolemia

Dyslipidemia

Treatments

Drug: simvastatin

Drug: torcetrapib/atorvastatin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00267254

A5091030

Details and patient eligibility

About

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of cholesterol medications to see how the different treatments compare to one another.

Full description

For additional information please call: 1-800-718-1021

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

eligible for statin treatment for LDL cholesterol by NCEP guidelines

Exclusion criteria

Women who are pregnant or lactating, or planning to become pregnant.
Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors.
Subjects with significant liver or kidney disease or significant heart failure.